Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of In Vivo BCMA/GPRC5D CAR-T in Relapsed/Refractory Plasma Cell Neoplasms
NCT07586709Phase 1Recruiting
- Sponsor
- Liping Dou
- Start
- May 2026
- Primary completion
- Mar 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SL4903 in Plasma cell neoplasms (PCN), sponsored by Liping Dou. Primary endpoints: Cytokine Release Syndrome at 1 month, Dose-limiting toxicities at 1 month and 2 more. Started May 2026; status: recruiting.
02
Drugs
SL4903
03
Conditions
Plasma cell neoplasms (PCN)
Beyond the preview
Go deeper on NCT07586709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07586709.